

**Tabelle 1 / Table 1**

Anzahl der gemeldeten Fälle und Inzidenzraten bezogen auf eine Million Kinder unter 15 Jahren aus der deutschen Wohnbevölkerung nach Diagnose auf Basis des ICCC-3, Alter und Geschlecht (2001-2010) /

Number of cases and incidence rates per million children under the age of 15 years in Germany by diagnoses classified according to ICCC-3, age, and sex (2001-2010)

---

**63****Tabelle 2 / Table 2**

Ausgewählte Kenngrößen für ausgewählte, systematisch registrierte, nicht in der ICCC-3 definierte nicht-maligne Diagnosen der Patienten unter 15 Jahren aus der deutschen Wohnbevölkerung (2001-2010) /

Summary data for systematically registered selected non-malignant diagnoses not defined in ICCC-3 of patients under 15 in Germany (2001-2010)

---

**73**



Tabelle 1:

Anzahl der gemeldeten Fälle und Inzidenzraten bezogen auf eine Million Kinder unter 15 Jahren aus der deutschen Wohnbevölkerung nach Diagnose auf Basis des ICCC-3, Alter und Geschlecht (2001-2010). *ICCC-3 extended Subklassifikation kursiv dargestellt.*

Number of cases and incidence rates per million children under the age of 15 years in Germany by diagnoses classified according to ICCC-3, age, and sex (2001-2010). *ICCC-3 extended subclassification in italics.*

Diagnoses	Sex	Sex ratio m / f	Number of cases							Incidence rates per million					Trial participants(%)	Survival probabilities(%)		
			N	Relative (%)	Group (%)				Age-specific				Age-stand. Cum.	0 - 14		5-year	10-year	
					0	1 - 4	5 - 9	10 - 14	0	1 - 4	5 - 9	10 - 14						World #
<b>All malignancies</b>	girls		7985	100	100	824	2765	2060	2336	242	195	109	113	147	2130	93.0	84	82
	boys		9891	100	100	1032	3304	2727	2828	288	221	137	130	173	2504	93.5	83	81
	<b>total</b>	<b>1.2</b>	<b>17876</b>	<b>100</b>	<b>100</b>	<b>1856</b>	<b>6069</b>	<b>4787</b>	<b>5164</b>	<b>266</b>	<b>208</b>	<b>123</b>	<b>121</b>	<b>160</b>	<b>2322</b>	<b>93.3</b>	<b>83</b>	<b>81</b>
<b>Leukaemias, myeloproliferative and myelodysplastic diseases</b>	girls		2757	35	100	134	1297	749	577	39	91	40	28	52	742	99.2	87	85
	boys		3332	34	100	174	1459	929	770	49	97	47	35	59	848	99.2	86	84
	<b>total</b>	<b>1.2</b>	<b>6089</b>	<b>34</b>	<b>100</b>	<b>308</b>	<b>2756</b>	<b>1678</b>	<b>1347</b>	<b>44</b>	<b>94</b>	<b>43</b>	<b>32</b>	<b>56</b>	<b>797</b>	<b>99.2</b>	<b>87</b>	<b>84</b>
Lymphoid leukaemias	girls		2145	27	78	64	1091	608	382	19	77	32	18	41	579	99.7	91	89
	boys		2622	27	79	70	1248	768	536	20	83	39	25	47	669	99.8	90	88
	<b>total</b>	<b>1.2</b>	<b>4767</b>	<b>27</b>	<b>78</b>	<b>134</b>	<b>2339</b>	<b>1376</b>	<b>918</b>	<b>19</b>	<b>80</b>	<b>35</b>	<b>22</b>	<b>44</b>	<b>625</b>	<b>99.8</b>	<b>90</b>	<b>88</b>
<i>Precursor cell leukaemias</i>	girls		2119	27	77	63	1086	591	379	19	76	31	18	40	572	99.8	91	89
	boys		2536	26	76	68	1227	735	506	19	82	37	23	45	647	99.8	90	88
	<b>total</b>	<b>1.2</b>	<b>4655</b>	<b>26</b>	<b>76</b>	<b>131</b>	<b>2313</b>	<b>1326</b>	<b>885</b>	<b>19</b>	<b>79</b>	<b>34</b>	<b>21</b>	<b>43</b>	<b>611</b>	<b>99.8</b>	<b>91</b>	<b>88</b>
<i>Mature B-cell leukaemias</i>	girls		25	0	1	1	5	17	2	0	0	1	0	0	7	100.0	-	-
	boys		86	1	3	2	21	33	30	1	1	2	1	1	21	98.8	85	85
	<b>total</b>	<b>3.4</b>	<b>111</b>	<b>1</b>	<b>2</b>	<b>3</b>	<b>26</b>	<b>50</b>	<b>32</b>	<b>0</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>14</b>	<b>99.1</b>	<b>84</b>	<b>84</b>
<i>Mature T-cell and NK cell leukaemias</i>	girls		1	0	0	0	0	0	1	0	0	0	0	0	0	-	-	-
	boys		0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-
	<b>total</b>	<b>0.0</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>-</b>	<b>-</b>	<b>-</b>
<i>Lymphoid leukaemia, NOS</i>	girls		0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-
	boys		0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-
	<b>total</b>	<b>-</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>-</b>	<b>-</b>	<b>-</b>
Acute myeloid leukaemias	girls		379	5	14	51	153	63	112	15	11	3	5	7	102	97.6	71	70
	boys		416	4	13	64	135	95	122	18	9	5	6	7	106	97.6	69	67
	<b>total</b>	<b>1.1</b>	<b>795</b>	<b>4</b>	<b>13</b>	<b>115</b>	<b>288</b>	<b>158</b>	<b>234</b>	<b>16</b>	<b>10</b>	<b>4</b>	<b>6</b>	<b>7</b>	<b>104</b>	<b>97.6</b>	<b>70</b>	<b>68</b>
Chronic myeloproliferative diseases	girls		43	1	2	0	5	18	20	0	0	1	1	1	11	88.4	-	-
	boys		37	0	1	0	5	11	21	0	0	1	1	1	9	83.8	-	-
	<b>total</b>	<b>0.9</b>	<b>80</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>10</b>	<b>29</b>	<b>41</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>10</b>	<b>86.3</b>	<b>-</b>	<b>-</b>
Myelodysplastic syndrome and other myeloproliferative diseases	girls		159	2	6	12	42	49	56	4	3	3	3	3	42	98.1	78	77
	boys		218	2	7	29	62	48	79	8	4	2	4	4	55	97.2	78	77
	<b>total</b>	<b>1.4</b>	<b>377</b>	<b>2</b>	<b>6</b>	<b>41</b>	<b>104</b>	<b>97</b>	<b>135</b>	<b>6</b>	<b>4</b>	<b>2</b>	<b>3</b>	<b>3</b>	<b>48</b>	<b>97.6</b>	<b>78</b>	<b>77</b>

# Standard: Segi world standard population

- insufficient data

Tabelle 1 Forts. Table 1 cont.

Diagnoses	Sex	Sex ratio m / f	Number of cases							Incidence rates per million					Trial participants(%)	Survival probabilities(%)		
			N	Relative (%)		Group (%)				Age-specific				Age-stand. Cum.		0 - 14	5-year	10-year
				0	1 - 4	5 - 9	10 - 14	0	1 - 4	5 - 9	10 - 14	World #						
Unspecified and other specified leukaemias	girls		31	0	1	7	6	11	7	2	0	1	0	1	8	100.0	65	-
	boys		39	0	1	11	9	7	12	3	1	0	1	1	10	100.0	64	64
	<b>total</b>	<b>1.3</b>	<b>70</b>	<b>0</b>	<b>1</b>	<b>18</b>	<b>15</b>	<b>18</b>	<b>19</b>	<b>3</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>9</b>	<b>100.0</b>	<b>65</b>	<b>65</b>
<b>Lymphomas and reticuloendothelial neoplasms</b>	girls		662	8	100	6	47	173	436	2	3	9	21	10	166	96.7	92	91
	boys		1375	14	100	7	174	515	679	2	12	26	31	21	333	96.2	94	93
	<b>total</b>	<b>2.1</b>	<b>2037</b>	<b>11</b>	<b>100</b>	<b>13</b>	<b>221</b>	<b>688</b>	<b>1115</b>	<b>2</b>	<b>8</b>	<b>18</b>	<b>26</b>	<b>16</b>	<b>252</b>	<b>96.4</b>	<b>94</b>	<b>92</b>
Hodgkin lymphomas	girls		343	4	52	0	3	49	291	0	0	3	14	5	84	98.0	98	-
	boys		521	5	38	0	30	153	338	0	2	8	15	8	124	97.1	99	98
	<b>total</b>	<b>1.5</b>	<b>864</b>	<b>5</b>	<b>42</b>	<b>0</b>	<b>33</b>	<b>202</b>	<b>629</b>	<b>0</b>	<b>1</b>	<b>5</b>	<b>15</b>	<b>6</b>	<b>104</b>	<b>97.5</b>	<b>98</b>	<b>97</b>
Non-Hodgkin lymphomas	girls		251	3	38	3	35	94	119	1	2	5	6	4	64	95.2	86	84
	boys		549	6	40	4	88	215	242	1	6	11	11	9	134	94.4	89	88
	<b>total</b>	<b>2.2</b>	<b>800</b>	<b>5</b>	<b>39</b>	<b>7</b>	<b>123</b>	<b>309</b>	<b>361</b>	<b>1</b>	<b>4</b>	<b>8</b>	<b>8</b>	<b>6</b>	<b>100</b>	<b>94.6</b>	<b>88</b>	<b>86</b>
<i>Precursor cell lymphomas</i>	girls		105	1	16	2	17	50	36	1	1	3	2	2	27	94.3	87	84
	boys		222	2	16	3	47	89	83	1	3	4	4	4	55	95.5	86	85
	<b>total</b>	<b>2.1</b>	<b>327</b>	<b>2</b>	<b>16</b>	<b>5</b>	<b>64</b>	<b>139</b>	<b>119</b>	<b>1</b>	<b>2</b>	<b>4</b>	<b>3</b>	<b>3</b>	<b>41</b>	<b>95.1</b>	<b>86</b>	<b>85</b>
<i>Mature B-cell lymphomas (except Burkitt lymphoma)</i>	girls		46	1	7	0	5	16	25	0	0	1	1	1	12	95.7	-	-
	boys		110	1	8	0	9	36	65	0	1	2	3	2	26	97.3	94	92
	<b>total</b>	<b>2.4</b>	<b>156</b>	<b>1</b>	<b>8</b>	<b>0</b>	<b>14</b>	<b>52</b>	<b>90</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>2</b>	<b>1</b>	<b>19</b>	<b>96.8</b>	<b>93</b>	<b>91</b>
<i>Mature T-cell and NK-cell lymphomas</i>	girls		59	1	9	1	7	12	39	0	0	1	2	1	15	94.9	-	-
	boys		106	1	8	1	18	44	43	0	1	2	2	2	26	93.4	87	87
	<b>total</b>	<b>1.8</b>	<b>165</b>	<b>1</b>	<b>8</b>	<b>2</b>	<b>25</b>	<b>56</b>	<b>82</b>	<b>0</b>	<b>1</b>	<b>1</b>	<b>2</b>	<b>1</b>	<b>21</b>	<b>93.9</b>	<b>85</b>	<b>84</b>
<i>Non-Hodgkin lymphomas, NOS</i>	girls		41	1	6	0	6	16	19	0	0	1	1	1	11	97.6	81	-
	boys		111	1	8	0	14	46	51	0	1	2	2	2	27	90.1	93	-
	<b>total</b>	<b>2.7</b>	<b>152</b>	<b>1</b>	<b>7</b>	<b>0</b>	<b>20</b>	<b>62</b>	<b>70</b>	<b>0</b>	<b>1</b>	<b>2</b>	<b>2</b>	<b>1</b>	<b>19</b>	<b>92.1</b>	<b>89</b>	<b>-</b>
Burkitt lymphoma	girls		63	1	10	1	8	29	25	0	1	2	1	1	16	100.0	93	93
	boys		298	3	22	0	55	145	98	0	4	7	4	5	74	98.3	95	95
	<b>total</b>	<b>4.7</b>	<b>361</b>	<b>2</b>	<b>18</b>	<b>1</b>	<b>63</b>	<b>174</b>	<b>123</b>	<b>0</b>	<b>2</b>	<b>4</b>	<b>3</b>	<b>3</b>	<b>46</b>	<b>98.6</b>	<b>95</b>	<b>94</b>
Miscellaneous lymphoreticular neoplasms	girls		4	0	1	2	0	1	1	1	0	0	0	0	1	50.0	-	-
	boys		6	0	0	3	1	1	1	1	0	0	0	0	2	83.3	-	-
	<b>total</b>	<b>1.5</b>	<b>10</b>	<b>0</b>	<b>1</b>	<b>5</b>	<b>1</b>	<b>2</b>	<b>2</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>70.0</b>	<b>-</b>	<b>-</b>
Unspecified lymphomas	girls		1	0	0	0	1	0	0	0	0	0	0	0	0	-	-	-
	boys		1	0	0	0	0	1	0	0	0	0	0	0	0	100.0	-	-
	<b>total</b>	<b>1.0</b>	<b>2</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>50.0</b>	<b>-</b>	<b>-</b>
<b>CNS and miscellaneous intracranial and intraspinal neoplasms</b>	girls		1856	23	100	139	539	615	563	41	38	33	27	33	491	88.5	78	74
	boys		2303	23	100	167	670	801	665	47	45	40	30	39	579	90.4	74	70
	<b>total</b>	<b>1.2</b>	<b>4159</b>	<b>23</b>	<b>100</b>	<b>306</b>	<b>1209</b>	<b>1416</b>	<b>1228</b>	<b>44</b>	<b>41</b>	<b>36</b>	<b>29</b>	<b>36</b>	<b>536</b>	<b>89.5</b>	<b>76</b>	<b>71</b>

Tabelle 1 Forts. Table 1 cont.

Diagnoses	Sex	Sex ratio m / f	Number of cases							Incidence rates per million					Trial participants(%)	Survival probabilities(%)		
			N	Relative (%)		Group (%)			Age-specific				Cum.	0 - 14		5-year	10-year	
				0	1 - 4	5 - 9	10 - 14	0	1 - 4	5 - 9	10 - 14	World #						
Ependymomas and choroid plexus tumour	girls		172	2	9	35	77	32	28	10	5	2	1	3	47	93.6	83	79
	boys		236	2	10	35	102	41	58	10	7	2	3	4	61	89.4	77	65
	<b>total</b>	<b>1.4</b>	<b>408</b>	<b>2</b>	<b>10</b>	<b>70</b>	<b>179</b>	<b>73</b>	<b>86</b>	<b>10</b>	<b>6</b>	<b>2</b>	<b>2</b>	<b>4</b>	<b>54</b>	<b>91.2</b>	<b>80</b>	<b>71</b>
<i>Ependymomas</i>	girls		129	2	7	13	63	28	25	4	4	1	1	3	35	97.7	81	79
	boys		193	2	8	15	88	38	52	4	6	2	2	3	49	90.7	76	64
	<b>total</b>	<b>1.5</b>	<b>322</b>	<b>2</b>	<b>8</b>	<b>28</b>	<b>151</b>	<b>66</b>	<b>77</b>	<b>4</b>	<b>5</b>	<b>2</b>	<b>2</b>	<b>3</b>	<b>42</b>	<b>93.5</b>	<b>78</b>	<b>70</b>
<i>Choroid plexus tumour</i>	girls		43	1	2	22	14	4	3	6	1	0	0	1	12	81.4	91	82
	boys		43	0	2	20	14	3	6	6	1	0	0	1	11	83.7	87	-
	<b>total</b>	<b>1.0</b>	<b>86</b>	<b>0</b>	<b>2</b>	<b>42</b>	<b>28</b>	<b>7</b>	<b>9</b>	<b>6</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>12</b>	<b>82.6</b>	<b>89</b>	<b>78</b>
Astrocytomas	girls		922	12	50	45	262	306	309	13	18	16	15	16	243	89.7	81	78
	boys		1040	11	45	52	288	386	314	15	19	19	14	18	260	91.0	79	76
	<b>total</b>	<b>1.1</b>	<b>1962</b>	<b>11</b>	<b>47</b>	<b>97</b>	<b>550</b>	<b>692</b>	<b>623</b>	<b>14</b>	<b>19</b>	<b>18</b>	<b>15</b>	<b>17</b>	<b>252</b>	<b>90.4</b>	<b>80</b>	<b>77</b>
Intracranial and intraspinal embryonal tumours	girls		318	4	17	37	105	116	60	11	7	6	3	6	86	90.9	68	61
	boys		513	5	22	51	170	206	86	14	11	10	4	9	131	93.4	66	58
	<b>total</b>	<b>1.6</b>	<b>831</b>	<b>5</b>	<b>20</b>	<b>88</b>	<b>275</b>	<b>322</b>	<b>146</b>	<b>13</b>	<b>9</b>	<b>8</b>	<b>3</b>	<b>8</b>	<b>109</b>	<b>92.4</b>	<b>66</b>	<b>59</b>
<i>Medulloblastomas</i>	girls		223	3	12	12	61	101	49	4	4	5	2	4	59	97.3	78	71
	boys		372	4	16	11	111	177	73	3	7	9	3	6	94	99.2	75	66
	<b>total</b>	<b>1.7</b>	<b>595</b>	<b>3</b>	<b>14</b>	<b>23</b>	<b>172</b>	<b>278</b>	<b>122</b>	<b>3</b>	<b>6</b>	<b>7</b>	<b>3</b>	<b>5</b>	<b>77</b>	<b>98.5</b>	<b>76</b>	<b>68</b>
<i>Primitive neuroectodermal tumour (PNET)</i>	girls		44	1	2	5	22	7	10	1	2	0	0	1	12	93.2	-	-
	boys		63	1	3	4	29	19	11	1	2	1	1	1	16	93.7	-	-
	<b>total</b>	<b>1.4</b>	<b>107</b>	<b>1</b>	<b>3</b>	<b>9</b>	<b>51</b>	<b>26</b>	<b>21</b>	<b>1</b>	<b>2</b>	<b>1</b>	<b>0</b>	<b>1</b>	<b>14</b>	<b>93.5</b>	<b>-</b>	<b>-</b>
<i>Medulloepithelioma</i>	girls		4	0	0	0	2	2	0	0	0	0	0	0	1	100.0	-	-
	boys		3	0	0	3	0	0	0	1	0	0	0	0	1	100.0	-	-
	<b>total</b>	<b>0.8</b>	<b>7</b>	<b>0</b>	<b>0</b>	<b>3</b>	<b>2</b>	<b>2</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>100.0</b>	<b>-</b>	<b>-</b>
<i>Atypical teratoid/rhabdoid tumour</i>	girls		47	1	3	20	20	6	1	6	1	0	0	1	13	57.4	-	-
	boys		75	1	3	33	30	10	2	9	2	1	0	2	20	64.0	-	-
	<b>total</b>	<b>1.6</b>	<b>122</b>	<b>1</b>	<b>3</b>	<b>53</b>	<b>50</b>	<b>16</b>	<b>3</b>	<b>8</b>	<b>2</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>17</b>	<b>61.5</b>	<b>-</b>	<b>-</b>
Other gliomas	girls		167	2	9	8	37	70	52	2	3	4	3	3	44	77.8	41	40
	boys		175	2	8	8	45	60	62	2	3	3	3	3	44	88.6	42	42
	<b>total</b>	<b>1.0</b>	<b>342</b>	<b>2</b>	<b>8</b>	<b>16</b>	<b>82</b>	<b>130</b>	<b>114</b>	<b>2</b>	<b>3</b>	<b>3</b>	<b>3</b>	<b>3</b>	<b>44</b>	<b>83.3</b>	<b>42</b>	<b>41</b>
<i>Oligodendrogliomas</i>	girls		10	0	1	0	0	6	4	0	0	0	0	0	3	60.0	-	-
	boys		10	0	0	0	1	3	6	0	0	0	0	0	2	80.0	-	-
	<b>total</b>	<b>1.0</b>	<b>20</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>9</b>	<b>10</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>2</b>	<b>70.0</b>	<b>-</b>	<b>-</b>
<i>Mixed and unspecified gliomas</i>	girls		150	2	8	7	35	64	44	2	2	3	2	3	39	78.0	36	35
	boys		158	2	7	7	44	57	50	2	3	3	2	3	39	89.9	39	39
	<b>total</b>	<b>1.1</b>	<b>308</b>	<b>2</b>	<b>7</b>	<b>14</b>	<b>79</b>	<b>121</b>	<b>94</b>	<b>2</b>	<b>3</b>	<b>3</b>	<b>2</b>	<b>3</b>	<b>39</b>	<b>84.1</b>	<b>38</b>	<b>37</b>

# Standard: Segi world standard population

- insufficient data

Tabelle 1 Forts. Table 1 cont.

Diagnoses	Sex	Sex ratio m / f	Number of cases							Incidence rates per million					Trial participants(%)	Survival probabilities(%)		
			N	Relative (%)		Group (%)			Age-specific				Age-stand. Cum.	0 - 14		5-year	10-year	
				0	1 - 4	5 - 9	10 - 14	0	1 - 4	5 - 9	10 - 14	World #						
<i>Neuroepithelial glial tumours of uncertain origin</i>	girls		7	0	0	1	2	0	4	0	0	0	0	2	100.0	-	-	
	boys		7	0	0	1	0	0	6	0	0	0	0	2	71.4	-	-	
	<b>total</b>	<b>1.0</b>	<b>14</b>	<b>0</b>	<b>0</b>	<b>2</b>	<b>2</b>	<b>0</b>	<b>10</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>2</b>	<b>85.7</b>	-	-	
Other specified intracranial and intraspinal neoplasms	girls		250	3	14	10	49	86	105	3	3	5	5	4	65	88.4	97	95
	boys		300	3	13	12	60	96	132	3	4	5	6	5	74	88.7	93	91
	<b>total</b>	<b>1.2</b>	<b>550</b>	<b>3</b>	<b>13</b>	<b>22</b>	<b>109</b>	<b>182</b>	<b>237</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>5</b>	<b>69</b>	<b>88.5</b>	<b>95</b>	<b>93</b>
<i>Pituitary adenomas and carcinomas</i>	girls		15	0	1	0	3	1	11	0	0	0	1	0	4	66.7	-	-
	boys		15	0	1	0	0	2	13	0	0	0	1	0	3	60.0	100	-
	<b>total</b>	<b>1.0</b>	<b>30</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>3</b>	<b>3</b>	<b>24</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>4</b>	<b>63.3</b>	<b>100</b>	-
<i>Tumours of the sellar region (craniopharyngiomas)</i>	girls		94	1	5	0	16	41	37	0	1	2	2	2	24	95.7	100	99
	boys		100	1	4	1	22	39	38	0	1	2	2	2	25	99.0	98	95
	<b>total</b>	<b>1.1</b>	<b>194</b>	<b>1</b>	<b>5</b>	<b>1</b>	<b>38</b>	<b>80</b>	<b>75</b>	<b>0</b>	<b>1</b>	<b>2</b>	<b>2</b>	<b>2</b>	<b>24</b>	<b>97.4</b>	<b>99</b>	<b>97</b>
<i>Pineal parenchymal tumours</i>	girls		13	0	1	1	2	6	4	0	0	0	0	0	3	100.0	-	-
	boys		17	0	1	0	7	3	7	0	0	0	0	0	4	76.5	-	-
	<b>total</b>	<b>1.3</b>	<b>30</b>	<b>0</b>	<b>1</b>	<b>1</b>	<b>9</b>	<b>9</b>	<b>11</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>4</b>	<b>86.7</b>	-	-
<i>Neuronal and mixed neuronal-glial tumours</i>	girls		100	1	5	9	23	27	41	3	2	1	2	2	26	85.0	98	95
	boys		143	1	6	11	25	43	64	3	2	2	3	2	35	89.5	93	93
	<b>total</b>	<b>1.4</b>	<b>243</b>	<b>1</b>	<b>6</b>	<b>20</b>	<b>48</b>	<b>70</b>	<b>105</b>	<b>3</b>	<b>2</b>	<b>2</b>	<b>2</b>	<b>2</b>	<b>31</b>	<b>87.7</b>	<b>95</b>	<b>94</b>
<i>Meningiomas</i>	girls		28	0	2	0	5	11	12	0	0	1	1	0	7	82.1	-	-
	boys		25	0	1	0	6	9	10	0	0	0	0	0	6	68.0	-	-
	<b>total</b>	<b>0.9</b>	<b>53</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>11</b>	<b>20</b>	<b>22</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>1</b>	<b>0</b>	<b>7</b>	<b>75.5</b>	-	-
Unspecified intracranial and intraspinal neoplasms	girls		27	0	2	4	9	5	9	1	1	0	0	1	7	51.9	-	-
	boys		39	0	2	9	5	12	13	3	0	1	1	1	10	64.1	65	-
	<b>total</b>	<b>1.4</b>	<b>66</b>	<b>0</b>	<b>2</b>	<b>13</b>	<b>14</b>	<b>17</b>	<b>22</b>	<b>2</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>1</b>	<b>9</b>	<b>59.1</b>	-	-
<b>Neuroblastoma and other peripheral nervous cell tumours</b>	girls		575	7	100	256	251	51	17	75	18	3	1	13	164	98.4	77	74
	boys		675	7	100	319	290	51	15	89	19	3	1	14	183	98.7	78	75
	<b>total</b>	<b>1.2</b>	<b>1250</b>	<b>7</b>	<b>100</b>	<b>575</b>	<b>541</b>	<b>102</b>	<b>32</b>	<b>82</b>	<b>19</b>	<b>3</b>	<b>1</b>	<b>13</b>	<b>173</b>	<b>98.6</b>	<b>77</b>	<b>75</b>
Neuroblastoma and ganglioneuroblastoma	girls		570	7	99	256	247	51	16	75	17	3	1	13	162	99.1	77	74
	boys		670	7	99	319	289	50	12	89	19	3	1	14	182	98.8	78	75
	<b>total</b>	<b>1.2</b>	<b>1240</b>	<b>7</b>	<b>99</b>	<b>575</b>	<b>536</b>	<b>101</b>	<b>28</b>	<b>82</b>	<b>18</b>	<b>3</b>	<b>1</b>	<b>13</b>	<b>172</b>	<b>99.0</b>	<b>78</b>	<b>75</b>
Other peripheral nervous cell tumours	girls		5	0	1	0	4	0	1	0	0	0	0	0	1	20.0	-	-
	boys		5	0	1	0	1	1	3	0	0	0	0	0	1	80.0	-	-
	<b>total</b>	<b>1.0</b>	<b>10</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>5</b>	<b>1</b>	<b>4</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>50.0</b>	-	-
<b>Retinoblastoma</b>	girls		179	2	100	76	94	9	0	22	7	0	0	4	51	-	99	99
	boys		217	2	100	97	109	9	2	27	7	0	0	5	59	-	97	96
	<b>total</b>	<b>1.2</b>	<b>396</b>	<b>2</b>	<b>100</b>	<b>173</b>	<b>203</b>	<b>18</b>	<b>2</b>	<b>25</b>	<b>7</b>	<b>0</b>	<b>0</b>	<b>4</b>	<b>55</b>	-	<b>98</b>	<b>98</b>

Tabelle 1 Forts. Table 1 cont.

Diagnoses	Sex	Sex ratio m / f	Number of cases							Incidence rates per million					Trial participants(%)	Survival probabilities(%)		
			N	Relative (%)		Group (%)			Age-specific				World #	Cum. 0 - 14		5-year	10-year	
				0	1 - 4	5 - 9	10 - 14	0	1 - 4	5 - 9	10 - 14							
Renal tumours	girls		523	7	100	72	292	127	32	21	21	7	2	11	145	98.9	95	94
	boys		481	5	100	95	266	91	29	27	18	5	1	9	127	97.1	92	91
	<b>total</b>	<b>0.9</b>	<b>1004</b>	<b>6</b>	<b>100</b>	<b>167</b>	<b>558</b>	<b>218</b>	<b>61</b>	<b>24</b>	<b>19</b>	<b>6</b>	<b>1</b>	<b>10</b>	<b>136</b>	<b>98.0</b>	<b>93</b>	<b>93</b>
Nephroblastoma and other non-epithelial renal tumours	girls		509	6	97	72	291	123	23	21	20	7	1	10	141	99.4	95	94
	boys		471	5	98	95	266	89	21	27	18	4	1	9	125	97.9	92	91
	<b>total</b>	<b>0.9</b>	<b>980</b>	<b>6</b>	<b>98</b>	<b>167</b>	<b>557</b>	<b>212</b>	<b>44</b>	<b>24</b>	<b>19</b>	<b>5</b>	<b>1</b>	<b>10</b>	<b>133</b>	<b>98.7</b>	<b>93</b>	<b>93</b>
<i>Nephroblastoma</i>	girls		501	6	96	68	288	122	23	20	20	6	1	10	139	99.6	95	95
	boys		458	5	95	91	262	86	19	25	18	4	1	9	121	98.3	93	92
	<b>total</b>	<b>0.9</b>	<b>959</b>	<b>5</b>	<b>96</b>	<b>159</b>	<b>550</b>	<b>208</b>	<b>42</b>	<b>23</b>	<b>19</b>	<b>5</b>	<b>1</b>	<b>10</b>	<b>130</b>	<b>99.0</b>	<b>94</b>	<b>94</b>
<i>Rhabdoid renal tumour</i>	girls		6	0	1	4	2	0	0	1	0	0	0	0	2	83.3	-	-
	boys		7	0	1	4	2	1	0	1	0	0	0	0	2	71.4	-	-
	<b>total</b>	<b>1.2</b>	<b>13</b>	<b>0</b>	<b>1</b>	<b>8</b>	<b>4</b>	<b>1</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>2</b>	<b>76.9</b>	-	-
<i>Kidney sarcomas</i>	girls		2	0	0	0	1	1	0	0	0	0	0	0	1	100.0	-	-
	boys		5	0	1	0	2	2	1	0	0	0	0	0	1	100.0	-	-
	<b>total</b>	<b>2.5</b>	<b>7</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>3</b>	<b>3</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>100.0</b>	-	-
<i>Peripheral neuroectodermal tumour (pPNET) of kidney</i>	girls		0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-
	boys		1	0	0	0	0	0	1	0	0	0	0	0	0	100.0	-	-
	<b>total</b>	<b>-</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>100.0</b>	-	-
Renal carcinomas	girls		14	0	3	0	1	4	9	0	0	0	0	0	4	78.6	-	-
	boys		10	0	2	0	0	2	8	0	0	0	0	0	2	60.0	-	-
	<b>total</b>	<b>0.7</b>	<b>24</b>	<b>0</b>	<b>2</b>	<b>0</b>	<b>1</b>	<b>6</b>	<b>17</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>3</b>	<b>70.8</b>	-	-
Unspecified malignant renal tumours	girls		0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-
	boys		0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-
	<b>total</b>	<b>-</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	-	-	-
Hepatic tumours	girls		87	1	100	24	45	7	11	7	3	0	1	2	24	95.4	66	64
	boys		130	1	100	36	58	15	21	10	4	1	1	3	34	96.2	71	68
	<b>total</b>	<b>1.5</b>	<b>217</b>	<b>1</b>	<b>100</b>	<b>60</b>	<b>103</b>	<b>22</b>	<b>32</b>	<b>9</b>	<b>4</b>	<b>1</b>	<b>1</b>	<b>2</b>	<b>29</b>	<b>95.9</b>	<b>69</b>	<b>66</b>
Hepatoblastoma	girls		73	1	84	24	43	4	2	7	3	0	0	2	21	98.6	68	68
	boys		106	1	82	36	56	7	7	10	4	0	0	2	28	99.1	79	78
	<b>total</b>	<b>1.5</b>	<b>179</b>	<b>1</b>	<b>83</b>	<b>60</b>	<b>99</b>	<b>11</b>	<b>9</b>	<b>9</b>	<b>3</b>	<b>0</b>	<b>0</b>	<b>2</b>	<b>25</b>	<b>98.9</b>	<b>75</b>	<b>74</b>
Hepatic carcinomas	girls		13	0	15	0	2	3	8	0	0	0	0	0	3	76.9	-	-
	boys		23	0	18	0	1	8	14	0	0	0	1	0	5	82.6	-	-
	<b>total</b>	<b>1.8</b>	<b>36</b>	<b>0</b>	<b>17</b>	<b>0</b>	<b>3</b>	<b>11</b>	<b>22</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>4</b>	<b>80.6</b>	-	-
Unspecified malignant hepatic tumours	girls		1	0	1	0	0	0	1	0	0	0	0	0	0	100.0	-	-
	boys		1	0	1	0	1	0	0	0	0	0	0	0	0	100.0	-	-
	<b>total</b>	<b>1.0</b>	<b>2</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>100.0</b>	-	-

# Standard: Segi world standard population

- insufficient data

Tabelle 1 Forts. Table 1 cont.

Diagnoses	Sex	Sex ratio m / f	Number of cases							Incidence rates per million					Trial participants(%)	Survival probabilities(%)		
			N	Relative (%)		Group (%)			Age-specific					Cum. 0 - 14		5-year	10-year	
				0	1 - 4	5 - 9	10 - 14	0	1 - 4	5 - 9	10 - 14	World #						
<b>Malignant bone tumours</b>	girls		379	5	100	1	24	93	261	0	2	5	13	6	95	97.4	74	70
	boys		423	4	100	4	27	116	276	1	2	6	13	6	101	97.9	72	68
	<b>total</b>	<b>1.1</b>	<b>802</b>	<b>5</b>	<b>100</b>	<b>5</b>	<b>51</b>	<b>209</b>	<b>537</b>	<b>1</b>	<b>2</b>	<b>5</b>	<b>13</b>	<b>6</b>	<b>98</b>	<b>97.6</b>	<b>73</b>	<b>69</b>
Osteosarcomas	girls		204	3	54	0	5	45	154	0	0	2	7	3	50	99.0	78	75
	boys		206	2	49	0	6	44	156	0	0	2	7	3	48	97.6	72	67
	<b>total</b>	<b>1.0</b>	<b>410</b>	<b>2</b>	<b>51</b>	<b>0</b>	<b>11</b>	<b>89</b>	<b>310</b>	<b>0</b>	<b>0</b>	<b>2</b>	<b>7</b>	<b>3</b>	<b>49</b>	<b>98.3</b>	<b>75</b>	<b>71</b>
Chondrosarcomas	girls		8	0	2	0	0	2	6	0	0	0	0	0	2	62.5	-	-
	boys		5	0	1	0	0	0	5	0	0	0	0	0	1	60.0	-	-
	<b>total</b>	<b>0.6</b>	<b>13</b>	<b>0</b>	<b>2</b>	<b>0</b>	<b>0</b>	<b>2</b>	<b>11</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>2</b>	<b>61.5</b>	-	-
Ewing tumour and related sarcomas of bone	girls		157	2	41	1	17	43	96	0	1	2	5	2	40	98.1	69	64
	boys		204	2	48	4	20	69	111	1	1	3	5	3	49	100.0	72	68
	<b>total</b>	<b>1.3</b>	<b>361</b>	<b>2</b>	<b>45</b>	<b>5</b>	<b>37</b>	<b>112</b>	<b>207</b>	<b>1</b>	<b>1</b>	<b>3</b>	<b>5</b>	<b>3</b>	<b>45</b>	<b>99.2</b>	<b>71</b>	<b>66</b>
Other specified malignant bone tumours	girls		8	0	2	0	2	2	4	0	0	0	0	0	2	100.0	-	-
	boys		5	0	1	0	1	3	1	0	0	0	0	0	1	80.0	-	-
	<b>total</b>	<b>0.6</b>	<b>13</b>	<b>0</b>	<b>2</b>	<b>0</b>	<b>3</b>	<b>5</b>	<b>5</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>2</b>	<b>92.3</b>	-	-
<i>Malignant fibrous neoplasms of bone</i>	girls		2	0	1	0	0	0	2	0	0	0	0	0	0	100.0	-	-
	boys		0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-
	<b>total</b>	<b>0.0</b>	<b>2</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>2</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>100.0</b>	-	-
<i>Malignant chordomas</i>	girls		5	0	1	0	2	2	1	0	0	0	0	0	1	100.0	-	-
	boys		4	0	1	0	0	3	1	0	0	0	0	0	1	75.0	-	-
	<b>total</b>	<b>0.8</b>	<b>9</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>2</b>	<b>5</b>	<b>2</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>88.9</b>	-	-
<i>Odontogenic malignant tumours</i>	girls		0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-
	boys		1	0	0	0	1	0	0	0	0	0	0	0	0	100.0	-	-
	<b>total</b>	<b>-</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>100.0</b>	-	-
<i>Miscellaneous malignant bone tumours</i>	girls		1	0	0	0	0	0	1	0	0	0	0	0	0	100.0	-	-
	boys		0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-
	<b>total</b>	<b>0.0</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>100.0</b>	-	-
Unspecified malignant bone tumours	girls		2	0	1	0	0	1	1	0	0	0	0	0	1	-	-	-
	boys		3	0	1	0	0	0	3	0	0	0	0	0	1	66.7	-	-
	<b>total</b>	<b>1.5</b>	<b>5</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>4</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>40.0</b>	-	-
<b>Soft tissue and other extrasosseous sarcomas</b>	girls		488	6	100	51	126	130	181	15	9	7	9	9	129	95.9	71	69
	boys		576	6	100	73	175	148	180	20	12	7	8	10	146	95.5	74	71
	<b>total</b>	<b>1.2</b>	<b>1064</b>	<b>6</b>	<b>100</b>	<b>124</b>	<b>301</b>	<b>278</b>	<b>361</b>	<b>18</b>	<b>10</b>	<b>7</b>	<b>8</b>	<b>9</b>	<b>137</b>	<b>95.7</b>	<b>73</b>	<b>70</b>
Rhabdomyosarcomas	girls		259	3	53	20	99	76	64	6	7	4	3	5	69	98.8	68	66
	boys		313	3	54	27	130	97	59	8	9	5	3	6	80	98.1	77	76
	<b>total</b>	<b>1.2</b>	<b>572</b>	<b>3</b>	<b>54</b>	<b>47</b>	<b>229</b>	<b>173</b>	<b>123</b>	<b>7</b>	<b>8</b>	<b>4</b>	<b>3</b>	<b>5</b>	<b>75</b>	<b>98.4</b>	<b>73</b>	<b>71</b>



Tabelle 1 Forts. Table 1 cont.

Diagnoses	Sex	Sex ratio m / f	N	Number of cases					Incidence rates per million					Trial participants(%)	Survival probabilities(%)			
				Relative (%)	Group (%)				Age-specific						Cum.	5-year	10-year	
					0	1 - 4	5 - 9	10 - 14	0	1 - 4	5 - 9	10 - 14	World #					0 - 14
Fibrosarcomas, peripheral nerve sheath tumours and other fibrous neoplasms	girls		52	1	11	12	5	9	26	4	0	0	1	1	14	86.5	-	-
	boys		57	1	10	17	8	9	23	5	1	0	1	1	14	87.7	75	-
	<b>total</b>	<b>1.1</b>	<b>109</b>	<b>1</b>	<b>10</b>	<b>29</b>	<b>13</b>	<b>18</b>	<b>49</b>	<b>4</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>1</b>	<b>14</b>	<b>87.2</b>	<b>68</b>	<b>64</b>
<i>Fibroblastic and myofibroblastic tumours</i>	girls		27	0	6	12	3	4	8	4	0	0	0	1	7	88.9	-	-
	boys		35	0	6	14	6	3	12	4	0	0	1	1	9	94.3	-	-
	<b>total</b>	<b>1.3</b>	<b>62</b>	<b>0</b>	<b>6</b>	<b>26</b>	<b>9</b>	<b>7</b>	<b>20</b>	<b>4</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>8</b>	<b>91.9</b>	<b>-</b>	<b>-</b>
<i>Nerve sheath tumours</i>	girls		25	0	5	0	2	5	18	0	0	0	1	0	6	84.0	-	-
	boys		22	0	4	3	2	6	11	1	0	0	1	0	5	77.3	-	-
	<b>total</b>	<b>0.9</b>	<b>47</b>	<b>0</b>	<b>4</b>	<b>3</b>	<b>4</b>	<b>11</b>	<b>29</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>6</b>	<b>80.9</b>	<b>-</b>	<b>-</b>
<i>Other fibrous neoplasms</i>	girls		0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-
	boys		0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-
	<b>total</b>	<b>-</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>-</b>	<b>-</b>	<b>-</b>
Kaposi sarcoma	girls		0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-
	boys		0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-
	<b>total</b>	<b>-</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>-</b>	<b>-</b>	<b>-</b>
Other specified soft tissue sarcomas	girls		137	2	28	16	13	34	74	5	1	2	4	2	35	96.4	83	79
	boys		165	2	29	21	32	35	77	6	2	2	4	3	41	93.3	67	62
	<b>total</b>	<b>1.2</b>	<b>302</b>	<b>2</b>	<b>28</b>	<b>37</b>	<b>45</b>	<b>69</b>	<b>151</b>	<b>5</b>	<b>2</b>	<b>2</b>	<b>4</b>	<b>3</b>	<b>38</b>	<b>94.7</b>	<b>75</b>	<b>70</b>
Unspecified soft tissue sarcomas	girls		40	1	8	3	9	11	17	1	1	1	1	1	10	87.5	-	-
	boys		41	0	7	8	5	7	21	2	0	0	1	1	10	95.1	70	63
	<b>total</b>	<b>1.0</b>	<b>81</b>	<b>1</b>	<b>8</b>	<b>11</b>	<b>14</b>	<b>18</b>	<b>38</b>	<b>2</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>1</b>	<b>10</b>	<b>91.4</b>	<b>65</b>	<b>62</b>
<b>Germ cell tumours, trophoblastic tumours and neoplasms of gonads</b>	girls		300	4	100	62	36	68	134	18	3	4	6	5	79	97.7	95	94
	boys		231	2	100	57	53	22	99	16	4	1	5	4	58	96.5	94	93
	<b>total</b>	<b>0.8</b>	<b>531</b>	<b>3</b>	<b>100</b>	<b>119</b>	<b>89</b>	<b>90</b>	<b>233</b>	<b>17</b>	<b>3</b>	<b>2</b>	<b>5</b>	<b>5</b>	<b>68</b>	<b>97.2</b>	<b>95</b>	<b>94</b>
Intracranial and intraspinal germ cell tumours	girls		61	1	20	3	2	26	30	1	0	1	1	1	16	96.7	92	88
	boys		95	1	41	1	5	21	68	0	0	1	3	1	22	94.7	89	87
	<b>total</b>	<b>1.6</b>	<b>156</b>	<b>1</b>	<b>29</b>	<b>4</b>	<b>7</b>	<b>47</b>	<b>98</b>	<b>1</b>	<b>0</b>	<b>1</b>	<b>2</b>	<b>1</b>	<b>19</b>	<b>95.5</b>	<b>90</b>	<b>87</b>
Malignant extracranial and extragonadal germ cell tumours	girls		95	1	32	59	26	3	7	17	2	0	0	2	27	95.8	95	94
	boys		51	1	22	27	16	1	7	8	1	0	0	1	14	98.0	98	-
	<b>total</b>	<b>0.5</b>	<b>146</b>	<b>1</b>	<b>28</b>	<b>86</b>	<b>42</b>	<b>4</b>	<b>14</b>	<b>12</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>2</b>	<b>20</b>	<b>96.6</b>	<b>96</b>	<b>95</b>
Malignant gonadal germ cell tumours	girls		139	2	46	0	8	38	93	0	1	2	4	2	35	100.0	99	98
	boys		85	1	37	29	32	0	24	8	2	0	1	2	22	97.6	98	98
	<b>total</b>	<b>0.6</b>	<b>224</b>	<b>1</b>	<b>42</b>	<b>29</b>	<b>40</b>	<b>38</b>	<b>117</b>	<b>4</b>	<b>1</b>	<b>1</b>	<b>3</b>	<b>2</b>	<b>28</b>	<b>99.1</b>	<b>98</b>	<b>98</b>
Gonadal carcinomas	girls		5	0	2	0	0	1	4	0	0	0	0	0	1	80.0	-	-
	boys		0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-
	<b>total</b>	<b>0.0</b>	<b>5</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>4</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>80.0</b>	<b>-</b>	<b>-</b>

# Standard: Segi world standard population

- insufficient data

Tabelle 1 Forts. Table 1 cont.

Diagnoses	Sex	Sex ratio m / f	N	Number of cases					Incidence rates per million					Trial participants(%)	Survival probabilities(%)			
				Relative (%)		Group (%)			Age-specific				Age-stand. World #		Cum. 0 - 14	5-year	10-year	
				0	1 - 4	5 - 9	10 - 14	0	1 - 4	5 - 9	10 - 14							
Other and unspecified malignant gonadal tumours	girls		0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	
	boys		0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	
	<b>total</b>	<b>-</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>-</b>	<b>-</b>	<b>-</b>	
<b>Other malignant epithelial neoplasms and malignant melanomas</b>	girls		171	2	100	3	12	37	119	1	1	2	6	3	43	63.7	90	86
	boys		138	1	100	3	16	29	90	1	1	1	4	2	33	59.4	79	-
	<b>total</b>	<b>0.8</b>	<b>309</b>	<b>2</b>	<b>100</b>	<b>6</b>	<b>28</b>	<b>66</b>	<b>209</b>	<b>1</b>	<b>1</b>	<b>2</b>	<b>5</b>	<b>2</b>	<b>38</b>	<b>61.8</b>	<b>85</b>	<b>81</b>
Adrenocortical carcinomas	girls		20	0	12	2	7	6	5	1	0	0	0	0	5	95.0	-	-
	boys		9	0	7	1	5	2	1	0	0	0	0	0	2	100.0	-	-
	<b>total</b>	<b>0.5</b>	<b>29</b>	<b>0</b>	<b>9</b>	<b>3</b>	<b>12</b>	<b>8</b>	<b>6</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>4</b>	<b>96.6</b>	<b>-</b>	<b>-</b>
Thyroid carcinomas	girls		80	1	47	0	1	21	58	0	0	1	3	1	20	90.0	98	94
	boys		51	1	37	1	2	12	36	0	0	1	2	1	12	90.2	92	-
	<b>total</b>	<b>0.6</b>	<b>131</b>	<b>1</b>	<b>42</b>	<b>1</b>	<b>3</b>	<b>33</b>	<b>94</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>2</b>	<b>1</b>	<b>16</b>	<b>90.1</b>	<b>96</b>	<b>92</b>
Nasopharyngeal carcinomas	girls		6	0	4	0	0	0	6	0	0	0	0	0	1	100.0	-	-
	boys		18	0	13	0	1	0	17	0	0	0	1	0	4	100.0	100	-
	<b>total</b>	<b>3.0</b>	<b>24</b>	<b>0</b>	<b>8</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>23</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>3</b>	<b>100.0</b>	<b>100</b>	<b>-</b>
Malignant melanomas	girls		23	0	14	1	4	5	13	0	0	0	1	0	6	-	94	-
	boys		23	0	17	1	6	6	10	0	0	0	0	0	6	-	-	-
	<b>total</b>	<b>1.0</b>	<b>46</b>	<b>0</b>	<b>15</b>	<b>2</b>	<b>10</b>	<b>11</b>	<b>23</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>6</b>	<b>-</b>	<b>82</b>	<b>-</b>
Skin carcinomas	girls		4	0	2	0	0	2	2	0	0	0	0	0	1	-	-	-
	boys		2	0	1	0	0	1	1	0	0	0	0	0	0	-	-	-
	<b>total</b>	<b>0.5</b>	<b>6</b>	<b>0</b>	<b>2</b>	<b>0</b>	<b>0</b>	<b>3</b>	<b>3</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>-</b>	<b>-</b>	<b>-</b>
Other and unspecified carcinomas	girls		38	1	22	0	0	3	35	0	0	0	2	1	9	31.6	79	-
	boys		35	0	25	0	2	8	25	0	0	0	1	1	8	25.7	60	-
	<b>total</b>	<b>0.9</b>	<b>73</b>	<b>0</b>	<b>24</b>	<b>0</b>	<b>2</b>	<b>11</b>	<b>60</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>1</b>	<b>9</b>	<b>28.8</b>	<b>69</b>	<b>-</b>
<i>Carcinomas of salivary glands</i>	girls		12	0	7	0	0	1	11	0	0	0	1	0	3	-	100	-
	boys		6	0	4	0	0	3	3	0	0	0	0	0	1	16.7	-	-
	<b>total</b>	<b>0.5</b>	<b>18</b>	<b>0</b>	<b>6</b>	<b>0</b>	<b>0</b>	<b>4</b>	<b>14</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>2</b>	<b>5.6</b>	<b>100</b>	<b>-</b>
<i>Carcinomas of colon and rectum</i>	girls		4	0	2	0	0	0	4	0	0	0	0	0	1	-	-	-
	boys		7	0	5	0	0	1	6	0	0	0	0	0	2	-	-	-
	<b>total</b>	<b>1.8</b>	<b>11</b>	<b>0</b>	<b>4</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>10</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>-</b>	<b>-</b>	<b>-</b>
<i>Carcinomas of appendix</i>	girls		1	0	1	0	0	0	1	0	0	0	0	0	0	100.0	-	-
	boys		3	0	2	0	0	1	2	0	0	0	0	0	1	100.0	-	-
	<b>total</b>	<b>3.0</b>	<b>4</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>3</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>100.0</b>	<b>-</b>	<b>-</b>	<b>-</b>
<i>Carcinomas of lung</i>	girls		3	0	2	0	0	0	3	0	0	0	0	0	1	100.0	-	-
	boys		5	0	4	0	0	2	3	0	0	0	0	0	1	20.0	-	-
	<b>total</b>	<b>1.7</b>	<b>8</b>	<b>0</b>	<b>3</b>	<b>0</b>	<b>0</b>	<b>2</b>	<b>6</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>50.0</b>	<b>-</b>	<b>-</b>

Tabelle 1 Forts. Table 1 cont.

Diagnoses	Sex	Sex ratio m / f	N	Number of cases					Incidence rates per million					Trial participants(%)	Survival probabilities(%)			
				Relative (%)	Group (%)	Age groups				Age-specific					Age-stand. World #	Cum. 0 - 14	5-year	10-year
						0	1 - 4	5 - 9	10 - 14	0	1 - 4	5 - 9	10 - 14					
<i>Carcinomas of thymus</i>	girls		1	0	1	0	0	0	1	0	0	0	0	0	0	-	-	-
	boys		1	0	1	0	0	0	1	0	0	0	0	0	0	-	-	-
	<b>total</b>	<b>1.0</b>	<b>2</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>2</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	-	-	-
<i>Carcinomas of breast</i>	girls		0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-
	boys		0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-
	<b>total</b>	<b>-</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	-	-	-
<i>Carcinomas of cervix uteri</i>	girls		1	0	1	0	0	0	1	0	0	0	0	0	0	-	-	-
	boys		0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-
	<b>total</b>	<b>0.0</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	-	-	-
<i>Carcinomas of bladder</i>	girls		0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-
	boys		0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-
	<b>total</b>	<b>-</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	-	-	-
<i>Carcinomas of eye</i>	girls		0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-
	boys		2	0	1	0	0	0	2	0	0	0	0	0	0	-	-	-
	<b>total</b>	<b>-</b>	<b>2</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>2</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	-	-	-
<i>Carcinomas of other specified sites</i>	girls		14	0	8	0	0	2	12	0	0	0	1	0	3	57.1	-	-
	boys		9	0	7	0	1	1	7	0	0	0	0	0	2	22.2	-	-
	<b>total</b>	<b>0.6</b>	<b>23</b>	<b>0</b>	<b>7</b>	<b>0</b>	<b>1</b>	<b>3</b>	<b>19</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>3</b>	<b>43.5</b>	-	-
<i>Carcinomas of unspecified site</i>	girls		2	0	1	0	0	0	2	0	0	0	0	0	0	-	-	-
	boys		2	0	1	0	1	0	1	0	0	0	0	0	0	100.0	-	-
	<b>total</b>	<b>1.0</b>	<b>4</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>3</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>50.0</b>	-	-
<b>Others and unspecified malignant neoplasms</b>	girls		8	0	100	0	2	1	5	0	0	0	0	0	2	62.5	-	-
	boys		10	0	100	0	7	1	2	0	0	0	0	0	3	80.0	-	-
	<b>total</b>	<b>1.3</b>	<b>18</b>	<b>0</b>	<b>100</b>	<b>0</b>	<b>9</b>	<b>2</b>	<b>7</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>2</b>	<b>72.2</b>	-	-
Other specified malignant tumours	girls		7	0	88	0	2	1	4	0	0	0	0	0	2	71.4	-	-
	boys		8	0	80	0	7	1	0	0	0	0	0	0	2	87.5	-	-
	<b>total</b>	<b>1.1</b>	<b>15</b>	<b>0</b>	<b>83</b>	<b>0</b>	<b>9</b>	<b>2</b>	<b>4</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>2</b>	<b>80.0</b>	-	-
<i>Gastrointestinal stromal tumour</i>	girls		2	0	25	0	0	0	2	0	0	0	0	0	0	100.0	-	-
	boys		0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-
	<b>total</b>	<b>0.0</b>	<b>2</b>	<b>0</b>	<b>11</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>2</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>100.0</b>	-	-
<i>Pancreatoblastoma</i>	girls		1	0	13	0	0	1	0	0	0	0	0	0	0	-	-	-
	boys		1	0	10	0	0	1	0	0	0	0	0	0	0	-	-	-
	<b>total</b>	<b>1.0</b>	<b>2</b>	<b>0</b>	<b>11</b>	<b>0</b>	<b>0</b>	<b>2</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	-	-	-
<i>Pulmonary blastoma and pleuropulmonary blastoma</i>	girls		2	0	25	0	2	0	0	0	0	0	0	0	1	100.0	-	-
	boys		6	0	60	0	6	0	0	0	0	0	0	0	2	100.0	-	-
	<b>total</b>	<b>3.0</b>	<b>8</b>	<b>0</b>	<b>44</b>	<b>0</b>	<b>8</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>100.0</b>	-	-

# Standard: Segi world standard population

- insufficient data

Tabelle 1 Forts. Table 1 cont.

Diagnoses	Sex	Sex ratio m / f	N	Number of cases				Incidence rates per million					Trial participants(%)	Survival probabilities(%)				
				Relative (%)	Group (%)	Age groups				Age-specific		Age-stand.		Cum.	0 - 14	5-year	10-year	
						0	1 - 4	5 - 9	10 - 14	0	1 - 4							5 - 9
<i>Other complex mixed and stromal neoplasms</i>	girls		1	0	13	0	0	0	1	0	0	0	0	0	0	100.0	-	-
	boys		1	0	10	0	1	0	0	0	0	0	0	0	0	100.0	-	-
	<b>total</b>	<b>1.0</b>	<b>2</b>	<b>0</b>	<b>11</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>100.0</b>	-	-
<i>Mesothelioma</i>	girls		1	0	13	0	0	0	1	0	0	0	0	0	0	-	-	-
	boys		0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-
	<b>total</b>	<b>0.0</b>	<b>1</b>	<b>0</b>	<b>6</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	-	-	-
<i>Other specified malignant tumours</i>	girls		0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-
	boys		0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-
	<b>total</b>	<b>-</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	-	-	-
Other unspecified malignant tumours	girls		1	0	13	0	0	0	1	0	0	0	0	0	0	-	-	-
	boys		2	0	20	0	0	0	2	0	0	0	0	0	0	50.0	-	-
	<b>total</b>	<b>2.0</b>	<b>3</b>	<b>0</b>	<b>17</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>3</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>33.3</b>	-	-	

# Standard: Segi world standard population

- insufficient data

Tabelle 2:

Ausgewählte Kenngrößen für ausgewählte, systematisch registrierte, nicht in der ICCC-3 definierte nicht-maligne Diagnosen der Patienten unter 15 Jahren aus der deutschen Wohnbevölkerung (2001-2010)

Summary data for selected systematically registered non-malignant diagnoses not defined in ICCC-3 of patients under 15 in Germany (2001-2010)

Diagnoses	Sex	Sex ratio m / f	N	Number of cases Age groups				Incidence rates per million Age groups					Trial participants(%)	
				0	1 - 4	5 - 9	10 - 14	0	1 - 4	5 - 9	10 - 14	World #		0 - 14
<b>All selected non-malignant diseases</b>	girls		717	217	138	165	197	64	10	9	10	14	194	92.2
	boys		666	181	186	141	158	51	12	7	7	12	172	89.8
	<b>total</b>	<b>0.9</b>	<b>1383</b>	<b>398</b>	<b>324</b>	<b>306</b>	<b>355</b>	<b>57</b>	<b>11</b>	<b>8</b>	<b>8</b>	<b>13</b>	<b>183</b>	<b>91.0</b>
<b>Non-malignant Langerhans cell histiocytosis</b>	girls		258	68	83	62	45	20	6	3	2	5	71	89.5
	boys		425	79	134	107	105	22	9	5	5	8	109	88.0
	<b>total</b>	<b>1.6</b>	<b>683</b>	<b>147</b>	<b>217</b>	<b>169</b>	<b>150</b>	<b>21</b>	<b>7</b>	<b>4</b>	<b>4</b>	<b>6</b>	<b>90</b>	<b>88.6</b>
<b>Benign/mature teratoma</b>	girls		352	123	35	68	126	36	2	4	6	7	94	95.2
	boys		113	70	24	8	11	20	2	0	1	2	30	92.9
	<b>total</b>	<b>0.3</b>	<b>465</b>	<b>193</b>	<b>59</b>	<b>76</b>	<b>137</b>	<b>28</b>	<b>2</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>62</b>	<b>94.6</b>
<b>Severe aplastic anaemia</b>	girls		77	2	17	33	25	1	1	2	1	1	20	97.4
	boys		95	2	28	25	40	1	2	1	2	2	23	95.8
	<b>total</b>	<b>1.2</b>	<b>172</b>	<b>4</b>	<b>45</b>	<b>58</b>	<b>65</b>	<b>1</b>	<b>2</b>	<b>1</b>	<b>2</b>	<b>1</b>	<b>22</b>	<b>96.5</b>
<b>Mesoblastic nephroma</b>	girls		19	18	1	0	0	5	0	0	0	0	6	84.2
	boys		29	28	0	1	0	8	0	0	0	1	8	89.7
	<b>total</b>	<b>1.5</b>	<b>48</b>	<b>46</b>	<b>1</b>	<b>1</b>	<b>0</b>	<b>7</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>7</b>	<b>87.5</b>

# Standard: Segi world standard population